TITLE:
Prevalence and Vaccination Status of Hepatitis B among HIV-Infected Patients in N’Djamena, Chad
AUTHORS:
Hidir Tidjani Abakar, Abakar Oumar Mahamat, Djelassem Ferdinand, Youssouf Abdessalam Ireboy, Lina Djonkreo, Moussa Adoum Aoudjali, Zita Aleyo Nodjikouambaye, Ahmat Mahamat Ahmat, Adji Boukar Tormalta, Hassoumi Manah, Mahamat Tahir Ngare Hassan, Agnes Tariam Djibangar, Ali Mahamat Moussa, Abderrazzack Adoum Fouda, Adawaye Chatté
KEYWORDS:
Prevalence, Vaccination, Co-Infection, HIV, HBsAg (HBV), N’Djamena, Chad
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.13 No.12,
December
24,
2025
ABSTRACT: The hepatitis B virus is transmitted in the same ways as HIV. With an estimated prevalence rate of over 8% in the general population, Chad is classified as a country with a high endemicity of hepatitis B virus infection. This study examines the prevalence of HIV/HBV co-infection and hepatitis B vaccination status among individuals who underwent voluntary HIV and hepatitis B screening at three HIV treatment centers in N’Djamena, Chad. Over an eight-month period, 2210 participants were tested, of whom 133 were co-infected with HIV/HBV, representing a prevalence of 6%. The prevalence of HIV/HBV co-infection was higher among females, 9.40%, with a sex ratio (M/F) of 0.60. The prevalence of HIV/HBeAg was 1%, while that of HIV/anti-HBcAb was 2.4%, HIV/anti-HBs antibodies was 100% negative. The average age of patients was 35 years, ranging from 18 to 70 years. The most represented age group was 25 to 35 years (36.8%). None of the co-infected participants had been vaccinated against HBV. HIV/HBV co-infection is considered a significant public health problem in Chad, requiring early diagnosis through awareness and screening campaigns among the general population, thereby enabling better care for patients co-infected with HIV/HBV.